Analysts predict that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report $0.57 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have made estimates for Vertex Pharmaceuticals’ earnings. The highest EPS estimate is $0.91 and the lowest is $0.46. Vertex Pharmaceuticals reported earnings of $0.35 per share in the same quarter last year, which indicates a positive year over year growth rate of 62.9%. The company is scheduled to announce its next quarterly earnings report on Wednesday, January 24th.

On average, analysts expect that Vertex Pharmaceuticals will report full-year earnings of $1.91 per share for the current fiscal year, with EPS estimates ranging from $1.79 to $2.23. For the next fiscal year, analysts expect that the company will post earnings of $2.83 per share, with EPS estimates ranging from $1.22 to $3.53. Zacks’ EPS calculations are an average based on a survey of research analysts that cover Vertex Pharmaceuticals.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.49. The firm had revenue of $578.20 million during the quarter, compared to the consensus estimate of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The business’s quarterly revenue was up 39.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.16 earnings per share.

Several brokerages have commented on VRTX. BMO Capital Markets reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, September 27th. Robert W. Baird reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. Needham & Company LLC restated a “buy” rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a report on Sunday, September 17th. Cowen restated a “buy” rating and set a $200.00 price target on shares of Vertex Pharmaceuticals in a report on Monday. Finally, Vetr cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price target on the stock. in a report on Monday, September 4th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-four have assigned a buy rating to the company. Vertex Pharmaceuticals currently has an average rating of “Buy” and an average target price of $173.22.

In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 6,290 shares of the company’s stock in a transaction on Friday, October 27th. The stock was sold at an average price of $143.97, for a total value of $905,571.30. Following the completion of the transaction, the executive vice president now owns 116,952 shares in the company, valued at approximately $16,837,579.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Ian F. Smith sold 2,125 shares of the company’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $155.61, for a total value of $330,671.25. Following the completion of the transaction, the chief operating officer now owns 118,013 shares of the company’s stock, valued at approximately $18,364,002.93. The disclosure for this sale can be found here. Insiders sold a total of 343,519 shares of company stock valued at $49,488,660 over the last three months. 1.80% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the company. Smithfield Trust Co. bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth $135,000. Northwestern Mutual Wealth Management Co. boosted its stake in Vertex Pharmaceuticals by 15.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after purchasing an additional 132 shares during the period. FNY Partners Fund LP boosted its stake in Vertex Pharmaceuticals by 900.0% in the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock worth $128,000 after purchasing an additional 900 shares during the period. FNY Managed Accounts LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth about $162,000. Finally, Fuller & Thaler Asset Management Inc. bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth about $198,000. Institutional investors own 93.33% of the company’s stock.

Shares of Vertex Pharmaceuticals (NASDAQ VRTX) traded down $0.77 during midday trading on Wednesday, reaching $140.91. The company’s stock had a trading volume of 1,010,200 shares, compared to its average volume of 1,788,797. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28. The firm has a market capitalization of $35,831.27, a P/E ratio of 236.13, a price-to-earnings-growth ratio of 3.39 and a beta of 1.58. Vertex Pharmaceuticals has a 12-month low of $71.46 and a 12-month high of $167.85.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Vertex Pharmaceuticals Incorporated (VRTX) to Announce $0.57 Earnings Per Share” was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/zacks-analysts-anticipate-vertex-pharmaceuticals-incorporated-vrtx-to-announce-0-57-earnings-per-share/1761499.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Get a free copy of the Zacks research report on Vertex Pharmaceuticals (VRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.